In case you’ve missed it, ASX COVID-era tech darling Bigtincan Holdings (ASX:BTH) has received a takeover offer from the ...

The US commercial launch of FB Dermatology’s LumiHeal ® technology, which has a Class II de novo device (US FDA) for surgical scar reduction, along with Kane Biotech’s coactiv+™ Antimicrobial Surgical ...

These items are hand-picked to make your shopping experience easier. ACM may be provided with compensation from ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

The earnings season for the drug/biotech sector is now in its final lap, with some large biotech and generic drug companies due to report their third-quarter 2024 results this week. The remaining ...

As election week jitters markets, Reddit celebrates its first-ever profit while an under-the-radar Aussie company shines.

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

Just over a year ago, New Zealand customs officials started to intercept batches of injectable medications labelled Fitaro ...

Editorial note: Forbes Advisor Australia may earn revenue from this story in the manner disclosed here. Read our advice disclaimer here. Australia’s annual inflation rate has fallen to its ...

The first high-speed mobile network, 3G, was launched in Australia in 2003 but has been overtaken by better and faster connections. While Vodafone began shutting down its 3G network between ...

This marks Novo Nordisk's second win this year in treating cardiovascular disease. The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic ...

And Novo Nordisk is asking the U.S. Food and Drug Administration (FDA) to bar compounding pharmacies from making off-brand versions of semaglutide, the active ingredient in its blockbuster weight ...